What The Vaccine Really Means For Work From Home Stocks

Work and learn from home stocks have had a solid run this year, as Covid-19 drives demand for connectivity, collaboration, and cybersecurity-related software. For perspective, our indicative theme of Work And Learn From Home Stocks is up by over 190% year-to-date on an equally weighted basis. However, a Coronavirus vaccine is looking like a real possibility in the coming quarters, following the surprisingly strong efficacy data for Pfizer’s
vaccine candidate which was released earlier this week. So what does this mean for work from home stocks? While

Read More

Canada bets on imports as home-grown COVID-19 vaccine heads to large-scale trials

TORONTO (Reuters) – Canada’s reliance on supply contracts to secure COVID-19 vaccines from drugmakers like Pfizer Inc has put daily life for Canadians, and prospects for the economy over the next year, in the hands of a few foreign companies facing overwhelming global demand.

Medicago employees harvest Nicotiana benthamiana plants to extract virus-like particles (VLP) in Medicago’s Durham Facility in Durham, North Carolina, U.S. in an undated photograph. Medicago/Handout via REUTERS.

As other governments pour hundreds of millions or billions into vaccine development, Canada has earmarked C$1 billion ($761 million) to buy doses abroad. Meanwhile, Quebec-based Medicago has worked with a shoestring budget on its home-grown, plant-based vaccine.

Medicago, owned by Japan’s Mitsubishi Tanabe Pharma and tobacco company Philip Morris, reported promising early trial data this week and said on Thursday it plans to begin large-scale studies. The vaccine uses an efficacy booster from GlaxoSmithKline called an adjuvant.

If pivotal

Read More

Wall Street Favoring Stay-At-Home Trade As Virus Cases Mount And Vaccine Still A Ways Away

Key Takeaways:

  • Initial jobless claims number came in at a less-than-expected 709,000
  • Headline, core CPI data show no monthly change in inflation
  • VIX, gold move higher; 10-year Treasury yield dips

This week, the stock market has seen a tug of war between growth stocks and value names as investors have been rethinking the balance between companies that would benefit from an economic reopening and those that would be helped if people stay at home longer.

This morning it seems that investors are leaning slightly toward the stay-at-home end of the pendulum swing, perhaps as a result of coronavirus cases that continue to mount ahead of the coldest months of the year and the realization that a vaccine likely will still take some time for approval and wide distribution. That likely means more economic pain for longer, especially for small businesses.

While the stock market this morning

Read More

Zoom And Other Stay-At-Home Stocks Pull Back After Positive Vaccine News. How Attractive Are They Now?

Certain companies have been clear beneficiaries of the coronavirus pandemic, as consumers’ behaviors changed and people stayed close to home. We don’t know when the market’s preferences will change or if they are temporary, but shares of stay-at-home stocks fell sharply on Monday following the release of encouraging coronavirus vaccine news.

The coronavirus pandemic, while better understood than it was at the beginning of the year, still presents significant uncertainty in terms of how it will impact society and the economy. Despite the long-term uncertainty, positive preliminary vaccine and antibody treatment news this week from major pharmaceutical companies led investors to abandon (at least temporarily) popular stay-at-home stocks Teladoc Health, UPS and Zoom Video.

Shares of Teladoc Health
traded nearly 14% lower on Monday, while Zoom Video Communications (ZM) declined more than 17%. The pullbacks came after Pfizer
and BioNTech SE (BNTX) reported that their coronavirus vaccine candidate

Read More

Coronavirus vaccine hope dampens prospects for corporate stay-at-home darlings

(Reuters) – The surge in shares of Netflix NFLX.O, Zoom ZM.O and other of this year’s stay-at-home corporate winners has been brought to a sudden halt by promising vaccine data suggesting a possible way out of the COVID-19 pandemic.

The jury was still out on Tuesday, however, as to whether that reverse, sparked by positive data from trials run by U.S. drugs giant Pfizer PFE.N and Germany’s BioNtech 22UAy.DE, would last.

Shares in video conferencing network Zoom fell 4% on Tuesday after plunging about 17% a day earlier. But both exercise bike maker Peloton, which sank more than 20% on Monday, and Netflix, actually gained ground on Tuesday.

Tech heavyweights from Google-parent Alphabet GOOGL.O to Apple AAPL.O and Amazon AMZN.O also suffered but have still mushroomed hugely in value this year.

“Even if a vaccine proves effective, inoculating a large enough

Read More